MA39422B1 - Modulateurs de cot et procédés d'utilisation associés - Google Patents

Modulateurs de cot et procédés d'utilisation associés

Info

Publication number
MA39422B1
MA39422B1 MA39422A MA39422A MA39422B1 MA 39422 B1 MA39422 B1 MA 39422B1 MA 39422 A MA39422 A MA 39422A MA 39422 A MA39422 A MA 39422A MA 39422 B1 MA39422 B1 MA 39422B1
Authority
MA
Morocco
Prior art keywords
associated methods
modulators
cost
cost modulators
methods
Prior art date
Application number
MA39422A
Other languages
English (en)
Other versions
MA39422A (fr
Inventor
Jeromy Cottell
John Link
James Taylor
Elizabeth Bacon
Gary Phillips
Musong Kim
Kirk Stevens
William Watkins
Gayatri Balan
Chien-Hung Chou
Christopher Clark
Thorsten Kirschberg
Scott Schroeder
Neil Squires
Nathan Wright
Sheila Zipfel
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MA39422A publication Critical patent/MA39422A/fr
Publication of MA39422B1 publication Critical patent/MA39422B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

La présente description concerne en général les modulateurs de cot (cancer osaka thyroïde) et les méthodes d'utilisation et de fabrication de celles-ci.
MA39422A 2015-07-06 2016-06-30 Modulateurs de cot et procédés d'utilisation associés MA39422B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189158P 2015-07-06 2015-07-06
US201562269060P 2015-12-17 2015-12-17
EP16738976.6A EP3191470B1 (fr) 2015-07-06 2016-06-30 Modulateurs de cot et procédés d'utilisation associés

Publications (2)

Publication Number Publication Date
MA39422A MA39422A (fr) 2017-07-19
MA39422B1 true MA39422B1 (fr) 2019-03-29

Family

ID=56411943

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39422A MA39422B1 (fr) 2015-07-06 2016-06-30 Modulateurs de cot et procédés d'utilisation associés

Country Status (40)

Country Link
US (6) US20170008905A1 (fr)
EP (3) EP3456717B1 (fr)
JP (5) JP6430060B2 (fr)
KR (5) KR101974793B1 (fr)
CN (3) CN107922390B (fr)
AU (4) AU2016290820B2 (fr)
BR (1) BR102016015656B1 (fr)
CA (1) CA2971640C (fr)
CL (1) CL2017003356A1 (fr)
CO (1) CO2017013351A2 (fr)
CR (1) CR20170599A (fr)
CU (1) CU20170172A7 (fr)
CY (1) CY1121750T1 (fr)
DK (1) DK3191470T3 (fr)
DO (1) DOP2017000311A (fr)
EA (1) EA036788B1 (fr)
EC (1) ECSP17084635A (fr)
ES (2) ES2734713T3 (fr)
HR (1) HRP20190853T1 (fr)
HU (1) HUE043310T2 (fr)
IL (4) IL293770B2 (fr)
LT (1) LT3191470T (fr)
MA (1) MA39422B1 (fr)
ME (1) ME03425B (fr)
MX (1) MX370984B (fr)
MY (1) MY196173A (fr)
NZ (2) NZ750707A (fr)
PE (1) PE20180462A1 (fr)
PH (2) PH12018500031A1 (fr)
PL (2) PL3456717T3 (fr)
PT (2) PT3456717T (fr)
RS (1) RS58639B1 (fr)
SA (1) SA517381350B1 (fr)
SG (1) SG11201702041PA (fr)
SI (2) SI3191470T1 (fr)
SV (1) SV2017005605A (fr)
TW (3) TWI748539B (fr)
UA (1) UA123010C2 (fr)
UY (1) UY36771A (fr)
WO (1) WO2017007689A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540343B2 (en) 2011-07-06 2017-01-10 Gilead Sciences, Inc. Compounds for the treatment of HIV
WO2016057931A1 (fr) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluorométhoxylation d'arènes via une migration intramoléculaire du groupe trifluorométhoxy
PT3456717T (pt) 2015-07-06 2021-05-26 Gilead Sciences Inc Derivado de 4,6-diamino-quinolina-3-carbonitrilo como modulador do cancro da tiróide de osaka (cot) para o tratamento de doenças inflamatórias
PT3319955T (pt) 2015-07-06 2021-01-05 Gilead Sciences Inc 6-amino-quinolino-3-carbonitrilos como moduladores de cot
US10059695B2 (en) 2016-06-30 2018-08-28 Gilead Sciences, Inc. Cot modulators and methods of use thereof
CN109890808B (zh) * 2016-08-19 2020-08-07 吉利德科学公司 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
EA036921B1 (ru) * 2017-02-10 2021-01-15 Джилид Сайэнс, Инк. Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич
CN108794516A (zh) * 2017-04-26 2018-11-13 上海时莱生物技术有限公司 硼酸和硼酸酯类化合物及其制备方法和用途
AR112413A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas sólidas de un inhibidor de la cápside del vih
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
JPWO2019065516A1 (ja) * 2017-09-26 2020-09-10 日本曹達株式会社 キノリン化合物および農園芸用殺菌剤
CA3089590C (fr) 2018-02-15 2022-12-06 Gilead Sciences, Inc. Derives de pyridine et leur utilisation pour le traitement d'une infection par le vih
EP3752496B1 (fr) 2018-02-16 2023-07-05 Gilead Sciences, Inc. Procédés et intermédiaires pour préparer un composé thérapeutique utile dans le traitement d'une infection virale par retroviridae
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
CN110294660B (zh) * 2018-03-23 2021-09-24 中国农业大学 一种含碳碳三键和/或碳氮三键的不饱和有机化合物的还原氘化方法
CN108658996A (zh) * 2018-06-25 2018-10-16 中国药科大学 一种氘代Fiduxosin的制备方法
US11944611B2 (en) 2018-07-16 2024-04-02 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
TW202235416A (zh) * 2019-06-14 2022-09-16 美商基利科學股份有限公司 Cot 調節劑及其使用方法
TW202122092A (zh) 2019-08-29 2021-06-16 瑞士商愛杜西亞製藥有限公司 α-D-吡喃半乳糖苷衍生物
AU2020391466B2 (en) 2019-11-26 2024-05-23 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
EP4126231A1 (fr) 2020-03-30 2023-02-08 Gilead Sciences, Inc. Formes solides de (s)-6-(((1-(bicyclo [1.1.1] pentan-1-yl) -1h-1,2,3-triazol-4-yl) 2-méthyl-1-oxo-1,2-dihydroisoquinolin-5-yl) méthyl))) amino) 8-chloro-(néopentylamino) quinoline-3-carb onitrile un composé inhibiteur de cot
CN115397824A (zh) * 2020-04-02 2022-11-25 吉利德科学公司 用于制备cot抑制剂化合物的方法
AU2021296607A1 (en) 2020-06-25 2023-01-19 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
AU2022228660A1 (en) 2021-03-03 2023-10-19 Idorsia Pharmaceuticals Ltd Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives
TW202304435A (zh) 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法
EP4352058A1 (fr) * 2021-06-11 2024-04-17 Neuronascent, Inc. Méthodes et compositions pour formulation lipidique de thérapies à petites molécules lipophiles du type hétérocyclique
TW202412779A (zh) 2021-12-03 2024-04-01 美商基利科學股份有限公司 用於hiv病毒感染之治療性化合物

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3930837A (en) 1971-12-31 1976-01-06 Ici Australia Limited 3-chloro-5-acetamidaisoquinoline as a herbicide
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
IT7819093A0 (it) 1977-01-10 1978-01-06 Ciba Geigy Prodotti antielmintici e loro impiego.
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP2634438B2 (ja) 1988-07-26 1997-07-23 三井東圧化学株式会社 不斉ビスオキサゾリルピリジン誘導体およびその製造方法
DE4014171A1 (de) 1990-05-03 1991-11-07 Basf Ag Cyanochinolinverbindungen
GB9310700D0 (en) 1993-05-24 1993-07-07 Zeneca Ltd Novel composition
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
WO1999011124A1 (fr) 1997-08-28 1999-03-11 Nissan Chemical Industries, Ltd. Agents antibacteriens et antifongiques, algicides et agents antisalissure a base de cyanoacrylate, a usage industriel
JP5035813B2 (ja) 1998-07-10 2012-09-26 マサチューセッツ インスティテュート オブ テクノロジー 金属用のリガンドおよびそれらに基づいて改善された金属触媒法
EP2896612A1 (fr) 1998-09-29 2015-07-22 Wyeth Holdings LLC Cyanoquinolines 3 substituées en tant qu'inhibiteurs de kinases de la protéine tyrosine
US6930100B2 (en) 2002-03-20 2005-08-16 Bristol-Myers Squibb Company Phosphate prodrugs of fluoroxindoles
KR100751604B1 (ko) 2003-03-03 2007-08-22 에프. 호프만-라 로슈 아게 5-ｈｔ6 조절자로서 사용되는 2,5- 및 2,6-치환된테트라하이드로아이소퀴놀린
SG145744A1 (en) 2003-08-19 2008-09-29 Wyeth Corp Process for the preparation of 4-amino-3- quinolinecarbonitriles
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
TW200529846A (en) * 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006124692A2 (fr) 2005-05-18 2006-11-23 Wyeth Inhibiteurs 3-cyanoquinoline de la tpl2 kinase et procedes de production et d'utilisation associes
CA2608362A1 (fr) 2005-05-18 2006-11-23 Wyeth Inhibiteurs de 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile de la tpl2 kinase et procedes de fabrication et d'utilisation de ceux-ci
JP2009513659A (ja) 2005-10-28 2009-04-02 アボット・ラボラトリーズ Ｔｒｐｖ１受容体を阻害するインダゾール誘導体
JP5255559B2 (ja) 2006-03-31 2013-08-07 アボット・ラボラトリーズ インダゾール化合物
WO2008055950A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Nouveaux inhibiteurs de la glutaminyl-cyclase
CN101583601B (zh) 2007-01-17 2013-06-05 香港科技大学 作为褪黑素受体mt1和mt2的亚型选择性激动剂的异喹诺酮化合物
GB0820856D0 (en) 2008-11-14 2008-12-24 Univ Leuven Kath Novel inhibitors of flavivirus replication
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
GB0922302D0 (en) 2009-12-22 2010-02-03 Imp Innovations Ltd Compounds
KR20120139767A (ko) 2010-03-09 2012-12-27 더 브로드 인스티튜트, 인코퍼레이티드 1차 암 요법에 대한 저항성을 갖는 또는 발달시키는 환자에서 암을 진단 및 치료하는 방법
ES2773693T3 (es) 2010-06-09 2020-07-14 Tianjin Hemay Oncology Pharmaceutical Co Ltd Derivados de cianoquinolina
JP6110787B2 (ja) 2011-05-10 2017-04-05 協和発酵キリン株式会社 ピリミドジアゼピノン化合物
CN103957711A (zh) 2011-07-04 2014-07-30 拜耳知识产权有限责任公司 取代的异喹啉酮、异喹啉二酮、异喹啉三酮和二氢异喹啉酮或其各自的盐作为活性剂对抗植物非生物胁迫的用途
EP2545964A1 (fr) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité
MX339763B (es) 2011-10-27 2016-06-07 Taisho Pharmaceutical Co Ltd Derivado de azol.
BR112014011351B1 (pt) 2011-11-11 2021-02-17 Gilead Apollo, Llc. inibidores de acc e usos dos mesmos
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
CN103483363B (zh) 2012-06-13 2016-12-21 上海赛迦化工产品有限公司 多样性的手性氨基硼酸及其制备方法和应用
WO2014064215A1 (fr) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibiteurs de la kinase tpl2 pour prévenir ou traiter le diabète et favoriser la survie de cellules β
CN103408572B (zh) 2013-07-12 2015-12-02 上海工程技术大学 手性氨基硼酸衍生物及其制备方法和应用
CN108947867A (zh) 2013-12-12 2018-12-07 卡利拉制药公司 双环烷基化合物及合成
CA2942144C (fr) 2014-03-07 2023-08-22 Kalyra Pharmaceuticals, Inc. Derives de propellane et synthese
EP3166938A4 (fr) * 2014-07-11 2018-01-17 Northwestern University Échafaudages 2-imidazolyl-pyrimidine en tant qu'inhibiteurs puissants et sélectifs de l'oxyde nitrique synthase neuronale
JP6833677B2 (ja) 2014-09-17 2021-02-24 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 二環式化合物
NZ729678A (en) 2014-09-24 2018-07-27 Gilead Sciences Inc Methods of treating non-alcoholic steatohepatitis using ask1 inhibitor in combination with a fxr agonist
EP3693366B8 (fr) 2014-12-23 2023-08-09 Gilead Sciences, Inc. Procédés de préparation d'inhibiteurs ask1
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
KR20170102299A (ko) 2015-01-09 2017-09-08 길리어드 아폴로, 엘엘씨 비-알콜성 지방간 질환의 치료를 위한 acc 억제제 조합 요법
JP6580145B2 (ja) 2015-01-16 2019-09-25 スリーエム イノベイティブ プロパティズ カンパニー グリッド出力を改善するグリッド行動を選択するためのシステム及び方法
PT3319955T (pt) * 2015-07-06 2021-01-05 Gilead Sciences Inc 6-amino-quinolino-3-carbonitrilos como moduladores de cot
PT3456717T (pt) 2015-07-06 2021-05-26 Gilead Sciences Inc Derivado de 4,6-diamino-quinolina-3-carbonitrilo como modulador do cancro da tiróide de osaka (cot) para o tratamento de doenças inflamatórias
DK3398598T3 (da) 2015-12-31 2022-07-11 Hitgen Inc Sulfonamidderivat og fremstillingsmetode og anvendelse deraf
EP3423456B1 (fr) 2016-03-02 2023-12-27 Gilead Apollo, LLC Formes solides d'un inhibiteur de thiénopyrimidinedione acc et leurs procédés de production
JP6738895B2 (ja) 2016-06-21 2020-08-12 Ｐｈｃホールディングス株式会社 カタラーゼ阻害剤及びカタラーゼ阻害剤を用いるアナライトの測定方法
US10059695B2 (en) 2016-06-30 2018-08-28 Gilead Sciences, Inc. Cot modulators and methods of use thereof
CN106512014A (zh) 2016-10-27 2017-03-22 武汉大学 肿瘤进展位点2在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
KR102424042B1 (ko) 2017-03-03 2022-07-22 길리애드 사이언시즈, 인코포레이티드 Acc 억제제 및 그의 고체 형태를 제조하는 방법
KR20220119520A (ko) 2017-03-28 2022-08-29 길리애드 사이언시즈, 인코포레이티드 간 질환을 치료하기 위한 치료 조합물
CN110520125A (zh) 2017-04-12 2019-11-29 吉利德科学公司 治疗肝病的方法
AU2018345817B2 (en) 2017-10-06 2021-10-28 Gilead Sciences, Inc. Combination therapy comprising an ACC inhibitor
US11524005B2 (en) 2019-02-19 2022-12-13 Gilead Sciences, Inc. Solid forms of FXR agonists
EP3934615A4 (fr) 2019-03-08 2023-01-25 The Regents Of The University Of California Compositions et méthodes de traitement de l'acné
TW202235416A (zh) 2019-06-14 2022-09-16 美商基利科學股份有限公司 Cot 調節劑及其使用方法
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
EP4126231A1 (fr) 2020-03-30 2023-02-08 Gilead Sciences, Inc. Formes solides de (s)-6-(((1-(bicyclo [1.1.1] pentan-1-yl) -1h-1,2,3-triazol-4-yl) 2-méthyl-1-oxo-1,2-dihydroisoquinolin-5-yl) méthyl))) amino) 8-chloro-(néopentylamino) quinoline-3-carb onitrile un composé inhibiteur de cot
CN115397824A (zh) 2020-04-02 2022-11-25 吉利德科学公司 用于制备cot抑制剂化合物的方法
TW202304435A (zh) 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法

Also Published As

Publication number Publication date
IL256433B (en) 2019-06-30
TWI634112B (zh) 2018-09-01
ES2872076T3 (es) 2021-11-02
US20170008905A1 (en) 2017-01-12
AU2022204050A1 (en) 2022-06-30
SA517381350B1 (ar) 2021-03-11
MA39422A (fr) 2017-07-19
EA201792613A1 (ru) 2018-06-29
CA2971640A1 (fr) 2017-01-12
IL293770A (en) 2022-08-01
BR102016015656B1 (pt) 2021-11-03
PT3456717T (pt) 2021-05-26
IL256433A (en) 2018-02-28
KR102073641B1 (ko) 2020-02-05
CN107922390A (zh) 2018-04-17
AU2019203122B2 (en) 2020-10-01
CR20170599A (es) 2018-02-28
KR20180022982A (ko) 2018-03-06
MY196173A (en) 2023-03-17
AU2016290820B2 (en) 2019-03-07
ES2734713T3 (es) 2019-12-11
PH12018500031B1 (en) 2018-07-09
TW201908305A (zh) 2019-03-01
HUE043310T2 (hu) 2019-08-28
IL266995A (en) 2019-07-31
SI3456717T1 (sl) 2021-08-31
US20230002407A1 (en) 2023-01-05
US11905299B2 (en) 2024-02-20
AU2016290820A1 (en) 2018-01-18
JP2021042252A (ja) 2021-03-18
EP3191470B1 (fr) 2019-02-27
EA036788B1 (ru) 2020-12-21
TW201712005A (zh) 2017-04-01
AU2019203122A1 (en) 2019-05-30
KR20190045416A (ko) 2019-05-02
TWI748539B (zh) 2021-12-01
ECSP17084635A (es) 2018-01-31
SG11201702041PA (en) 2017-04-27
AU2020257055A1 (en) 2020-11-12
US20200123172A1 (en) 2020-04-23
JP6781221B2 (ja) 2020-11-04
JP7138155B2 (ja) 2022-09-15
RS58639B1 (sr) 2019-05-31
MX370984B (es) 2020-01-09
SI3191470T1 (sl) 2019-04-30
JP2018520161A (ja) 2018-07-26
IL266995B (en) 2020-05-31
TWI699361B (zh) 2020-07-21
US20170152240A1 (en) 2017-06-01
US20190248807A1 (en) 2019-08-15
PE20180462A1 (es) 2018-03-06
CN114380799A (zh) 2022-04-22
KR101974793B1 (ko) 2019-05-02
IL293770B1 (en) 2023-03-01
AU2022204050B2 (en) 2024-04-18
WO2017007689A1 (fr) 2017-01-12
PH12018500031A1 (en) 2018-07-09
BR102016015656A2 (pt) 2020-09-24
JP2018193405A (ja) 2018-12-06
MX2017004737A (es) 2017-06-19
TW202114673A (zh) 2021-04-16
JP6430060B2 (ja) 2018-11-28
US20180237455A1 (en) 2018-08-23
ME03425B (fr) 2020-01-20
SV2017005605A (es) 2018-07-18
UA123010C2 (uk) 2021-02-03
PH12020551397A1 (en) 2021-08-16
HRP20190853T1 (hr) 2019-06-28
CO2017013351A2 (es) 2018-05-21
KR102443575B1 (ko) 2022-09-16
CA2971640C (fr) 2020-09-22
JP2022082816A (ja) 2022-06-02
DK3191470T3 (en) 2019-04-15
KR20240008398A (ko) 2024-01-18
PT3191470T (pt) 2019-06-05
US9878995B2 (en) 2018-01-30
KR20200013120A (ko) 2020-02-05
EP3896064A1 (fr) 2021-10-20
CN107922390B (zh) 2019-05-10
KR20220129667A (ko) 2022-09-23
CN109879859A (zh) 2019-06-14
LT3191470T (lt) 2019-05-10
NZ738525A (en) 2019-03-29
DOP2017000311A (es) 2018-01-15
CU20170172A7 (es) 2018-06-05
UY36771A (es) 2017-01-31
IL293770B2 (en) 2023-07-01
CY1121750T1 (el) 2020-07-31
CL2017003356A1 (es) 2018-07-06
JP6906021B2 (ja) 2021-07-21
US11066414B2 (en) 2021-07-20
EP3456717B1 (fr) 2021-03-17
JP2019178178A (ja) 2019-10-17
AU2020257055B2 (en) 2022-03-31
CN109879859B (zh) 2022-01-25
PL3456717T3 (pl) 2021-10-25
EP3456717A1 (fr) 2019-03-20
IL274568B (en) 2022-07-01
NZ750707A (en) 2023-09-29
IL274568A (en) 2020-06-30
PL3191470T3 (pl) 2019-08-30
EP3191470A1 (fr) 2017-07-19

Similar Documents

Publication Publication Date Title
MA39422B1 (fr) Modulateurs de cot et procédés d'utilisation associés
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
MA43187A (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MY191169A (en) Anti-fcrh5 antibodies
MA40938A (fr) Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
MA39095A1 (fr) Anticorps et immunoconjugués anti-cd33
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
MA39248B1 (fr) Anticorps anti-jagged1 et procédés d'utilisation correspondants
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
EA201990615A1 (ru) Пирролобензодиазепиновые конъюгаты
MA40671A1 (fr) Anticorps anti-c10orf54 et leurs utilisations
BR112017008666A2 (pt) anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
BR112018071586A2 (pt) uso de beta-agonistas da tireoide
CL2020003364A1 (es) Tratamiento antidiabético cardiovascular y renal seguro
MA39141A1 (fr) Anticorps anti-tau(ps422) humanisés et leurs méthodes d'utilisation
UA104973U (uk) Біологічно активна добавка шумілова
EA201792492A1 (ru) Aml-антигены и их применение
MY195448A (en) New Anti-Sirpa Antibodies and Their Therapeutic Applications
EA202092495A1 (ru) МОДУЛЯТОРЫ Cot И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
MA39078A1 (fr) Anticorps anti-cd3 et méthodes d'utilisation